Paper Details

  1. Home
  2. Paper Details

Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.

Author: Abu-HashyehAhmad, Al-HasanSara, AlhousaniMohammad, AlsharediMohamed, MalikSaad Ullah, MustafaBisher, PoznanskiNoah John, RothDanielle Frances

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study aims to assess the efficacy and safety of direct oral anticoagulants (DOACs) and other oral anticoagulants in preventing recurrent venous thromboembolism (VTE) in high-risk patients with chronic kidney disease (CKD). The study will explore the potential of DOACs as a treatment option for VTE in CKD patients.
Paper Details　
Original Abstract of the Article :
Chronic kidney disease (CKD) increases the risk of venous thromboembolism (VTE) among affected patients. Vitamin K antagonists (VKA) and warfarin remains the main stay of its treatment. Due to novelty and unclear risk-to-benefit ratio of direct oral anti-coagulants (DOAC), they remain underutilized ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.thromres.2020.11.036

データ提供：米国国立医学図書館（NLM）

Oral Anticoagulants in Chronic Kidney Disease: A Journey Through the Sands of Risk

Chronic kidney disease (CKD) significantly increases the risk of venous thromboembolism (VTE), a serious condition involving blood clots. This study aims to assess the efficacy and safety of direct oral anticoagulants (DOACs) in preventing recurrent VTE in patients with CKD. The researchers conducted a systematic review and meta-analysis of available evidence to evaluate the effectiveness and safety of DOACs compared to vitamin K antagonists (VKAs) in this patient population. The study highlights the growing role of DOACs in the management of VTE in patients with CKD, while acknowledging the need for further research to fully understand the risks and benefits of these medications.

Navigating the Sands of Risk

The study explores the complex landscape of anticoagulation therapy in patients with CKD, highlighting the ongoing quest for safe and effective treatment options. The researchers, like explorers charting a course through a vast and unforgiving desert, have provided valuable insights into the risks and benefits of different treatment approaches. The study emphasizes the need for careful consideration of individual patient factors to determine the most appropriate treatment strategy.

Navigating the Sands of Risk

The study underscores the importance of ongoing research to optimize the management of VTE in patients with CKD. For patients, the study highlights the growing availability of DOACs as treatment options, though it emphasizes the importance of close monitoring and individualized care. The study's findings underscore the need to navigate the complex terrain of VTE treatment in CKD with caution and careful attention to potential risks and benefits.

Dr. Camel's Conclusion

This study sheds light on the challenging landscape of anticoagulation therapy in patients with CKD. The researchers have meticulously examined the available evidence, like a camel caravan carefully evaluating each oasis for its potential. The study offers valuable insights into the evolving role of DOACs in the management of VTE, emphasizing the need for careful navigation of the complex terrain of risk and benefit.

Date :
  1. Date Completed 2021-06-17
  2. Date Revised 2021-06-17
Further Info :

Pubmed ID

33310644

DOI: Digital Object Identifier

10.1016/j.thromres.2020.11.036

Related Literature

Article Analysis
・Side Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.